PMN310 aims to deliver a safer, next-generation treatment by targeting toxic amyloid-beta in early-stage Alzheimer’s patients Shares of ProMIS Neurosciences...

Regencell Bioscience’s Stock Whipsaws Again Amid 17,000% Surge in 2025

byLuca Blaumann

July 7, 2025

Following a 38-to-1 stock split and explosive rally, the biotech firm's volatile trading persists despite a multi-year loss streak Regencell...

KindlyMD and Nakamoto Merge to Launch Largest Bitcoin Treasury Initiative in Public Markets

byLuca Blaumann

May 12, 2025

$710 Million Raised as David Bailey Leads Ambitious Plan to Transform Bitcoin Adoption Through Public Equity In a landmark move...

Hims & Hers Health Doubles Revenue in Q1 2025, Raises Full-Year Outlook

byLuca Blaumann

May 5, 2025

Surging subscriber growth and profitability prompt ambitious long-term targets for 2030 Hims & Hers Health, Inc. (HIMS), a leading digital...

Novo Nordisk Expands Wegovy Access Through Telehealth Providers

byLuca Blaumann

April 29, 2025

Partnership with Hims & Hers, Ro, and LifeMD aims to capture patients as compounded versions disappear Novo Nordisk (NVO) is...

Biotech Stocks Slide as FDA’s Peter Marks Resigns

byLuca Blaumann

March 31, 2025

Wall Street Reacts to Leadership Uncertainty in Biopharma Approvals The resignation of Peter Marks, director of the FDA’s Center for...

China Bans U.S. Gene Sequencer Imports Amid Rising Trade Tensions

byLiliana Vida

March 4, 2025

Illumina Takes a Hit as Beijing Retaliates Against U.S. Tariffs China announced on Tuesday a ban on imports of genetic...

HCW Biologics Gains FDA Clearance for First-in-Human Trial of Novel Alopecia Areata Treatment

byLuca Blaumann

February 3, 2025

Phase 1 Trial of HCW9302 Marks a Milestone in Autoimmune Disease Research HCW Biologics (HCWB), a clinical-stage biopharmaceutical company specializing...